VAD therapy 20/20: moving beyond the myopic view of a nascent therapy.
Repository Usage Stats
The past five years have seen remarkable growth in the use of durable, continuous flow left ventricular assist devices (LVAD) with associated improvements in mortality, quality of life, functionality and end-organ function. To sustain the growth of this important therapy, the LVAD community must now address key issues focused around the costs of LVAD care, refined patient selection, and reducing complications associated with this therapy. In this perspective piece, we discuss many of these issues.
Published Version (Please cite this version)10.3978/j.issn.2225-319X.2014.08.22
Publication InfoDeVore, Adam David; Milano, Carmelo Alessio; & Rogers, JG (2014). VAD therapy 20/20: moving beyond the myopic view of a nascent therapy. Ann Cardiothorac Surg, 3(6). pp. 603-605. 10.3978/j.issn.2225-319X.2014.08.22. Retrieved from https://hdl.handle.net/10161/11078.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Assistant Professor of Medicine
Adam D. DeVore, MD, MHS Dr. DeVore is a cardiologist and Assistant Professor of Medicine in the Department of Medicine, Division of Cardiology, at Duke University School of Medicine. His clinical interests include caring for patients and families with heart failure, including those with left ventricular assist devices and heart transplants. He is involved in and leads multiple large studies of patients with heart failure at both Duke University Medical Center and the
Professor of Surgery
Alphabetical list of authors with Scholars@Duke profiles.